Matches in Nanopublications for { ?s ?p "[Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and ≤ 10 pack years and quit ≥ 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- NP485964.RAB36G9WdZr3Tx-x4Y2mjOxKJrY2738eJePXVuIX2nWv0130_assertion description "[Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and ≤ 10 pack years and quit ≥ 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP485964.RAB36G9WdZr3Tx-x4Y2mjOxKJrY2738eJePXVuIX2nWv0130_provenance.
- NP389576.RAi9KNlZDGsYzDD_kcGTL-TGtB3bsqg5SeyAfCzW8hpiw130_assertion description "[Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and ≤ 10 pack years and quit ≥ 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP389576.RAi9KNlZDGsYzDD_kcGTL-TGtB3bsqg5SeyAfCzW8hpiw130_provenance.
- NP706417.RA7qoB1IrPoKyUCd9ZMGogDxCHBLyWPdNt9OvY0M4v_K0130_assertion description "[Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and ≤ 10 pack years and quit ≥ 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP706417.RA7qoB1IrPoKyUCd9ZMGogDxCHBLyWPdNt9OvY0M4v_K0130_provenance.